Article Information
- Received May 22, 2018
- Revision received October 19, 2018
- Accepted October 23, 2018
- First published November 19, 2018.
- Version of record published January 9, 2019.
Author Information
Author contributions
Author contributions: A.S.G. wrote the first draft of the paper; A.S.G., M.J.K., J.G., and M.A.M. edited the paper; A.S.G., M.J.K., J.G., and M.A.M. designed research; A.S.G. performed research; A.S.G. analyzed data; A.S.G. and M.A.M. wrote the paper.
↵*J.G. and M.A.M. contributed equally to this work.
Disclosures
- Received May 22, 2018.
- Revision received October 19, 2018.
- Accepted October 23, 2018.
A.S.G. was supported by an IoPPN-MRC Excellence award. M.J.K. was supported by Medical Research Council Fellowship Grant MR/J008915/1. M.A.M. and M.J.K. were supported by the National Institute for Health Research Biomedical Research Centre at South London and the Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research, or the Department of Health and Social Care. J.G. was supported by the British Academy. We thank the study participants for time and commitment to the study; Dr. Ottavia Dipasquale for assistance with the receptor density analysis; and South London & Maudsley NHS Trust Pharmacy for managing the supply and access to MDMA.
The authors declare no competing financial interests.
- Correspondence should be addressed to Dr. Anthony S. Gabay, Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology & Neuroscience (089), De Crespigny Park, London SE5 8AF, UK. anthony.a.gabay{at}kcl.ac.uk
Other Version
- previous version (November 19, 2018).
- You are viewing the most recent version of this article.
Online Impact
